Profile data is unavailable for this security.
About the company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-31.75m
- Incorporated2011
- Employees17.00
- LocationTempest Therapeutics Inc2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE 94005United StatesUSA
- Phone+1 (415) 798-8589
- Fax+1 (302) 655-5049
- Websitehttps://www.tempesttx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aligos Therapeutics Inc | 7.97m | -75.74m | 32.54m | 68.00 | -- | 0.9515 | -- | 4.08 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Quince Therapeutics Inc | 0.00 | -53.12m | 32.89m | 32.00 | -- | 0.7003 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 33.14m | 4.00 | -- | 9.52 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Clene Inc. | 442.00k | -30.46m | 33.58m | 82.00 | -- | -- | -- | 75.97 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Ocean Biomedical Inc | 0.00 | -98.59m | 34.30m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 34.38m | 73.00 | -- | 1.03 | -- | 14.59 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 34.58m | 163.00 | -- | 0.1695 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Dyadic International Inc | 1.80m | -7.74m | 35.08m | 7.00 | -- | 11.07 | -- | 19.44 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 35.11m | -- | -- | 3.37 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Elevation Oncology Inc | 0.00 | -39.70m | 35.45m | 29.00 | -- | 0.4051 | -- | -- | -0.8399 | -0.8399 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -35.30 | -- | -37.14 | -- | -- | -- | -- | -- | -- | -25.25 | 0.2765 | -- | -- | -- | 51.93 | -- | -- | -- |
Curis Inc | 10.16m | -47.57m | 35.46m | 48.00 | -- | -- | -- | 3.49 | -8.24 | -8.24 | 1.76 | -0.1175 | 0.1509 | -- | 4.12 | 211,687.50 | -70.62 | -37.25 | -90.04 | -41.12 | 98.30 | 96.05 | -468.18 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -31.75m | 35.54m | 17.00 | -- | 2.04 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 37.75m | 4.00 | -- | -- | -- | 55.20 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Gain Therapeutics Inc | 0.00 | -21.60m | 38.18m | 29.00 | -- | 3.19 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 38.38m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Jun 2024 | 546.54k | 2.17% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 174.01k | 0.69% |
Geode Capital Management LLCas of 30 Jun 2024 | 154.24k | 0.61% |
FIL Investment Advisors (UK) Ltd.as of 30 Jun 2024 | 129.58k | 0.51% |
Ikarian Capital LLCas of 30 Jun 2024 | 105.60k | 0.42% |
GSA Capital Partners LLPas of 30 Jun 2024 | 101.04k | 0.40% |
Citadel Securities LLCas of 30 Jun 2024 | 92.23k | 0.37% |
Virtu Americas LLCas of 30 Jun 2024 | 62.03k | 0.25% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 61.12k | 0.24% |
Davenport & Co. LLCas of 30 Jun 2024 | 50.00k | 0.20% |